Raina Nakova Fichorova, Ph.D., M.D.
This page shows the publications co-authored by Raina Fichorova and Daniel Cramer.
Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES). Gynecol Oncol. 2021 04; 161(1):282-290.
Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk. Cancer Causes Control. 2013 Nov; 24(11):1911-23.
Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA. Cancer Causes Control. 2021 Mar; 32(3):299-309.
Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiol Biomarkers Prev. 2018 07; 27(7):790-804.
Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control. 2010 Aug; 21(8):1193-201.
Development and validation of circulating CA125 prediction models in postmenopausal women. J Ovarian Res. 2019 Nov 26; 12(1):116.
Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiol Biomarkers Prev. 2019 06; 28(6):1076-1085.
Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. Int J Cancer. 2018 04 01; 142(7):1355-1360.
Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. J Ovarian Res. 2017 Mar 20; 10(1):20.
A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clin Cancer Res. 2016 Sep 15; 22(18):4664-75.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.